Paul Matisse reports Biohaven's KV7 epilepsy drug is on partial clinical hold with phase 3 data coming soon.
“Biohaven had what looks like a small setback, but might be more meaningful in contacts for their KV7 drug and epilepsy, which is put on partial clinical hold. It's in phase three and the data are coming quite soon, put on partial clinical hold, kind of some opacity around the disclosure here.”
→ Read the source episode
Our resolution criterion
disputableBiohaven announces resolution of partial clinical hold and/or releases phase 3 efficacy and safety data for their KV7 inhibitor in epilepsy
More from Biotech Hangout
Tarsus Pharmaceuticals' Alkias phase three Northstar study for gilderretinol will report data in H2 2029.
Ten X will meet with EMA to explore enriched patient populations for HFpEF drug following failed phase three.
Eric Schmidt predicts the HARMONY three study for evanesquimab will read out positively in 6-9 months.
Daphne Zohar predicts Heidi Overton's FDA commissioner confirmation hearings will occur after the Senate summer recess.
Brian Skorney predicts Lilly's Lp(a) CVOT data may read out in 2029.
Brian Skorney predicts Novartis will present full DM1 trial dataset at WMS (World Muscle Society) conference in Japan within a few weeks.
Summaries are ours; the quote is a verbatim transcript excerpt. Our resolution criteria are editorial and disputable. How this works.